The Shareek investment program launched in Saudi Arabia this week may help diversification efforts, but there is a risk it leads to a misallocation of resources that damages longer-run growth prospects. Elsewhere, the announcement that the UAE will produce the Sinopharm COVID-19 vaccine should help to maintain rapid vaccine progress there and help other countries in the region, allowing restrictions to be lifted sooner than we currently assume. Finally, while the decision by the IMF to increase the size of Jordan’s deal is positive news, the Fund is likely to demand further austerity, which will weigh on economic growth.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to gain:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services